Valentina Boni M.D., PhD
Valentina Boni, M.D., Ph.D., is a Medical Oncologist and Principal Investigator of START Madrid – CIOCC. She is also Clinical Associated Professor of Medicine at the CEU University San Pablo, Madrid, Spain.
Valentina Boni earned her Medical Degree cum Laude in 2005 at the Catholic University of Rome, Italy. In November 2009 she completed her trainer in Medical Oncology at the Agostino Gemelli University Hospital in Rome, Italy. From 2009 to 2011, she joined the Garcia-Foncillas’s Pharmacogenomic Program at the Center for Applied Medical Research (CIMA), in Pamplona, Spain, as a Clinical Researcher working on translational oncology centered on predictive biomarkers discovery, solid tumor expression profiling and modulation of drug response. In 2009, she was awarded PhD from the University of Navarra for her work on the role of miRNAsas predictive biomarkers in metastatic colorectal cancer. In 2013, she joined the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (Flims), Switzerland.
From 2011 till now, she has been working at START Madrid-CIOCC as a Clinical Investigator at the Early Drug Development Unit and she was involved in more than 100 Phase I clinical trials, including First in Human trial, immunotherapy trials, combinations of targeted therapies, immunotherapies, biomarker-driven trials, and trials in molecularly selected populations with special emphasis on breast cancer, gynecological tumors and melanoma.
She is currently the Principal Investigator/Co-Investigator of over 60 early phase clinical trials of novel anticancer agents for patients with advanced solid tumors and she has pioneered the development of new anticancer drugs now approved such as VITRAKVI® (larotrectinib). She has authored and co-authored several papers in peer-reviewed journals including the New England Journal of Medicine and Nature. She has been a Faculty Member for the American Society of Clinical Oncology and she is now coordinating the Molecular Tumor Board, centered on molecular analysis of patient tumors and molecular prescreening including circulating DNA and expression profiling by Nanostring in order to select the best anti-cancer therapy for any single patient and initiating the precision medicine in the field of immuno-oncology, with new aims in epigenetic and cancer stem cells.
Dr. Boni is a member of the American Society of Clinical Oncology and of the European Society of Medical Oncology. She serves as an ad-hoc reviewer of various oncology journals and sits in the Scientific Advisory Board of innovative biotechnology companies. She is currently a member of the Scientific Program Committee for SOLTI Innovative Breast Cancer Research.